A. Trousseau, Lectures on Clinical Medicine, Delivered at the Hotel-Dieu, pp.281-295

S. Bouillaud and . De-l, Obliteration des veines et de son influence sur la formation des hydropisies partielles: consideration sur la hydropisies passive et general. Arch, Gen. Med, vol.1823, pp.188-204

J. W. Blom, C. J. Doggen, S. Osanto, and F. R. Rosendaal, Malignancies, prothrombotic mutations, and the risk of venous thrombosis, JAMA, vol.293, pp.715-722, 2005.

A. Falanga, L. Russo, V. Milesi, and A. Vignoli, Mechanisms and risk factors of thrombosis in cancer, Crit. Rev. Oncol. Hematol, vol.118, pp.79-83, 2017.

A. Falanga, F. Schieppati, and D. Russo, Cancer Tissue Procoagulant Mechanisms and the Hypercoagulable State of Patients with Cancer, Semin. Thromb. Hemost, vol.41, pp.756-764, 2015.

K. Date, J. Hall, J. Greenman, A. Maraveyas, and L. A. Madden, Tumour and microparticle tissue factor expression and cancer thrombosis, Thromb. Res, vol.131, pp.109-115, 2013.

A. Falanga, M. Panova-noeva, and L. Russo, Procoagulant mechanisms in tumour cells, Best Pract. Res. Clin. Haematol, vol.22, pp.49-60, 2009.

E. Campello, L. Spiezia, C. M. Radu, C. Bulato, M. Castelli et al., Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism, Thromb. Res, vol.127, pp.473-477, 2011.

O. Königsbrügge, I. Pabinger, and C. Ay, Risk factors for venous thromboembolism in cancer: novel findings from the Vienna Cancer and Thrombosis Study (CATS), Thromb. Res, vol.133, pp.39-43, 2014.

A. A. Khorana, Venous thromboembolism and prognosis in cancer, Thromb. Res, vol.125, pp.490-493, 2010.

D. Farge, H. Bounameaux, B. Brenner, F. Cajfinger, P. Debourdeau et al., International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer, Lancet Oncol, vol.17, pp.452-466, 2016.

L. A. Kahale, M. B. Hakoum, I. G. Tsolakian, C. F. Matar, I. Terrenato et al., Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer, Cochrane Database Syst. Rev, vol.6, 2018.

E. A. Akl, N. Labedi, M. Barba, I. Terrenato, F. Sperati et al., Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer, Cochrane Database Syst. Rev, 2011.

J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers et al., Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012, Int. J. Cancer, vol.136, pp.359-386, 2015.

R. L. Siegel, K. D. Miller, and A. Jemal, Cancer statistics, vol.68, pp.7-30, 2018.

R. Pan, M. Zhu, C. Yu, J. Lv, Y. Guo et al., Cancer incidence and mortality: A cohort study in China, Int. J. Cancer, vol.141, pp.1315-1323, 2008.

B. Gupta, N. W. Johnson, and N. Kumar, Global Epidemiology of Head and Neck Cancers: A Continuing Challenge, Oncology, vol.91, pp.13-23, 2016.

D. J. Weatherspoon, A. Chattopadhyay, S. Boroumand, and I. Garcia, Oral cavity and oropharyngeal cancer incidence trends and disparities in the United States, Cancer Epidemiol, vol.39, pp.497-504, 2000.

S. Jiang and Y. Dong, Human papillomavirus and oral squamous cell carcinoma: A review of HPV-positive oral squamous cell carcinoma and possible strategies for future, Curr. Probl. Cancer, vol.41, pp.323-327, 2017.

H. T. Sørensen, L. Mellemkjaer, F. H. Steffensen, J. H. Olsen, and G. L. Nielsen, The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism, N. Engl. J. Med, vol.338, pp.1169-1173, 1998.

J. A. Baron, G. Gridley, E. Weiderpass, O. Nyrén, and M. Linet, Venous thromboembolism and cancer, Lancet Lond. Engl, vol.351, pp.1077-1080, 1998.

S. Paneesha, A. Mcmanus, R. Arya, N. Scriven, T. Farren et al., Frequency, demographics and risk (according to tumour type or site) of cancer-associated thrombosis among patients seen at outpatient DVT clinics, Thromb. Haemost, vol.103, pp.338-343, 2010.

P. Prandoni, A. W. Lensing, H. R. Büller, A. Cogo, M. H. Prins et al., Deep-vein thrombosis and the incidence of subsequent symptomatic cancer, N. Engl. J. Med, vol.327, pp.1128-1133, 1992.

A. Piccioli, A. W. Lensing, M. H. Prins, A. Falanga, G. L. Scannapieco et al., Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial, J. Thromb. Haemost. JTH, vol.2, pp.884-889, 2004.

J. Trujillo-santos, P. Prandoni, K. Rivron-guillot, P. Román, R. Sánchez et al., Clinical outcome in patients with venous thromboembolism and hidden cancer: findings from the RIETE Registry, J. Thromb. Haemost. JTH, vol.6, pp.251-255, 2008.

H. T. Sørensen, C. Svaerke, D. K. Farkas, C. F. Christiansen, L. Pedersen et al., Superficial and deep venous thrombosis, pulmonary embolism and subsequent risk of cancer, Eur. J. Cancer Oxf. Engl, vol.48, pp.586-593, 1990.

T. M. Petterson, R. S. Marks, A. A. Ashrani, K. R. Bailey, and J. A. Heit, Risk of site-specific cancer in incident venous thromboembolism: a population-based study, Thromb. Res, vol.135, pp.472-478, 2015.

P. Robin, P. Le-roux, B. Planquette, S. Accassat, P. Roy et al., Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial, Lancet Oncol, vol.17, pp.193-199, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01282875

L. Sun, W. Chung, C. Lin, J. Liang, and C. Kao, Unprovoked venous thromboembolism and subsequent cancer risk: a population-based cohort study, J. Thromb. Haemost. JTH, vol.14, pp.495-503, 2016.

P. Sandén, P. J. Svensson, and A. Själander, Venous thromboembolism and cancer risk, J. Thromb. Thrombolysis, vol.43, pp.68-73, 2017.

L. Jara-palomares, R. Otero, D. Jimenez, M. Carrier, I. Tzoran et al., Development of a Risk Prediction Score for Occult Cancer in Patients With VTE, vol.151, pp.564-571, 2017.

A. Delluc, J. Ianotto, C. Tromeur, C. De-moreuil, F. Couturaud et al., Real-world incidence of cancer following a first unprovoked venous thrombosis: Results from the EPIGETBO study, Thromb. Res, vol.164, pp.79-84, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02052699

N. Levitan, A. Dowlati, S. C. Remick, H. I. Tahsildar, L. D. Sivinski et al., Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data, Medicine, vol.78, pp.285-291, 1999.

S. Sallah, J. Y. Wan, and N. P. Nguyen, Venous thrombosis in patients with solid tumors: Determination of frequency and characteristics, Thromb. Haemost, vol.87, pp.575-579, 2002.

A. A. Khorana, C. W. Francis, E. Culakova, R. I. Fisher, N. M. Kuderer et al., Thromboembolism in hospitalized neutropenic cancer patients, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.24, pp.484-490, 2006.

P. D. Stein, A. Beemath, F. A. Meyers, E. Skaf, J. Sanchez et al., Incidence of venous thromboembolism in patients hospitalized with cancer, Am. J. Med, vol.119, pp.60-68, 2006.

A. A. Khorana, C. W. Francis, E. Culakova, N. M. Kuderer, and G. H. Lyman, Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients, Cancer, vol.110, pp.2339-2346, 2007.

A. J. Walker, T. R. Card, J. West, C. Crooks, and M. J. Grainge, Incidence of venous thromboembolism in patients with cancer-A cohort study using linked United Kingdom databases, Eur. J. Cancer Oxf. Engl, vol.49, pp.1404-1413, 1990.

T. Chew, C. Gau, Y. Wen, L. Shen, C. D. Mullins et al., Epidemiology, clinical profile and treatment patterns of venous thromboembolism in cancer patients in Taiwan: a population-based study, BMC Cancer, vol.15, 2015.

W. P. Innis and T. D. Anderson, Deep venous thrombosis and pulmonary embolism in otolaryngologic patients, Am. J. Otolaryngol, vol.30, pp.230-233, 2009.

P. Hennessey, Y. R. Semenov, and C. G. Gourin, The effect of deep venous thrombosis on short-term outcomes and cost of care after head and neck cancer surgery, Laryngoscope, vol.122, pp.2199-2204, 2012.

L. Thai, K. Mccarn, W. Stott, T. Watts, M. K. Wax et al., Venous thromboembolism in patients with head and neck cancer after surgery, Head Neck, vol.35, pp.4-9, 2013.

H. Gavriel, E. Thompson, S. Kleid, S. Chan, and A. Sizeland, Safety of thromboprophylaxis after oncologic head and neck surgery. Study of 1018 patients, Head Neck, vol.35, pp.1410-1414, 2013.

D. R. Clayburgh, W. Stott, T. Cordiero, R. Park, K. Detwiller et al., Prospective study of venous thromboembolism in patients with head and neck cancer after surgery, JAMA Otolaryngol.-Head Neck Surg, vol.139, pp.1143-1150, 2013.

J. N. Lodders, S. Parmar, N. L. Stienen, T. J. Martin, K. H. Karagozoglu et al., Incidence of symptomatic venous thromboembolism in oncological oral and maxillofacial operations: Retrospective analysis, Br. J. Oral Maxillofac. Surg, vol.53, pp.244-250, 2015.

N. S. Ali, A. Nawaz, M. Junaid, M. Kazi, and S. Akhtar, Venous Thromboembolism-Incidence of Deep Venous Thrombosis and Pulmonary Embolism in Patients with Head and Neck Cancer: A Tertiary Care Experience in Pakistan, Int. Arch. Otorhinolaryngol, vol.19, pp.200-204, 2015.

Y. Kakei, M. Akashi, T. Hasegawa, T. Minamikawa, S. Usami et al., Incidence of Venous Thromboembolism After Oral Oncologic Surgery With Simultaneous Reconstruction, J. Oral Maxillofac. Surg. Off. J. Am. Assoc. Oral Maxillofac. Surg, vol.74, pp.212-217, 2016.

Y. Wang, J. Liu, X. Yin, J. Hu, E. Kalfarentzos et al., Venous thromboembolism after oral and maxillofacial oncologic surgery: Report and analysis of 14 cases in Chinese population, Med. Oral Patol. Oral Cirugia Bucal, vol.22, pp.115-121, 2017.

P. A. Thodiyil and A. K. Kakkar, Variation in relative risk of venous thromboembolism in different cancers, Thromb. Haemost, vol.87, pp.1076-1077, 2002.

C. D. Fuller, S. J. Wang, C. R. Thomas, H. T. Hoffman, R. S. Weber et al., Conditional survival in head and neck squamous cell carcinoma: results from the SEER dataset 1973-1998, Cancer, vol.109, pp.1331-1343, 2007.

D. P. Skarsgard, P. A. Groome, W. J. Mackillop, S. Zhou, D. Rothwell et al., Cancers of the upper aerodigestive tract in Ontario, Canada, and the United States, Cancer, vol.88, pp.1728-1738, 2000.

D. H. Christensen, K. Veres, A. G. Ording, J. O. Jørgensen, S. C. Cannegieter et al., Risk of cancer in patients with thyroid disease and venous thromboembolism, Clin. Epidemiol, vol.10, pp.907-915, 2018.

J. W. Blom, S. Osanto, and F. R. Rosendaal, The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma, J. Thromb. Haemost. JTH, vol.2, pp.1760-1765, 2004.

G. W. Huang, H. T. Nong, M. Nakamura, and T. Kosugi, Enhancement of platelet aggregation in patients with nasopharyngeal carcinoma, Auris. Nasus. Larynx, vol.21, pp.173-177, 1994.

J. Gregson, S. Kaptoge, T. Bolton, L. Pennells, P. Willeit et al., Cardiovascular Risk Factors Associated With Venous Thromboembolism, JAMA Cardiol, vol.21, pp.89-93, 2019.

A. G. Holst, G. Jensen, and E. Prescott, Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study, Circulation, vol.121, pp.1896-1903, 2010.

T. Forouzanfar, M. W. Heymans, A. Van-schuilenburg, S. Zweegman, and E. A. Schulten, Incidence of venous thromboembolism in oral and maxillofacial surgery: A retrospective analysis, Int. J. Oral Maxillofac. Surg, vol.39, pp.256-259, 2010.

V. Bahl, A. G. Shuman, H. M. Hu, C. R. Jackson, C. J. Pannucci et al., Chemoprophylaxis for venous thromboembolism in otolaryngology, JAMA Otolaryngol.-Head Neck Surg, vol.140, pp.999-1005, 2014.

A. A. Khorana, C. W. Francis, E. Culakova, and G. H. Lyman, Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study, Cancer, vol.104, pp.2822-2829, 2005.

J. A. Heit, M. D. Silverstein, D. N. Mohr, T. M. Petterson, W. M. O'fallon et al., Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study, Arch. Intern. Med, vol.160, pp.809-815, 2000.

G. H. Lyman, A. A. Khorana, N. M. Kuderer, A. Y. Lee, J. I. Arcelus et al., Venous thromboembolism prophylaxis and treatment in patients with cancer, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.31, pp.2189-2204, 2013.

J. D. Cramer, A. G. Shuman, and M. J. Brenner, Antithrombotic Therapy for Venous Thromboembolism and Prevention of Thrombosis in Otolaryngology-Head and Neck Surgery: State of the Art Review

. Otolaryngol, Head Neck Surg. Off. J. Am. Acad. Otolaryngol.-Head Neck Surg, vol.158, pp.627-636, 2018.

A. Robson, J. Sturman, P. Williamson, P. Conboy, S. Penney et al., Pre-treatment clinical assessment in head and neck cancer: United Kingdom National Multidisciplinary Guidelines, J. Laryngol. Otol, vol.130, pp.13-22, 2016.

S. Schulman, W. Ageno, and S. V. Konstantinides, Venous thromboembolism: Past, present and future, Thromb. Haemost, vol.117, pp.1219-1229, 2017.

D. N. Tukaye, H. Brink, and R. Baliga, Venous thromboembolism in cancer patients: Risk assessment, prevention and management, Future Cardiol, vol.12, pp.221-235, 2016.

L. Gal, G. Righini, M. Wells, and P. S. , Scoring Systems for Diagnosis of Acute Venous Thromboembolism, Semin. Thromb. Hemost, vol.43, pp.479-485, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02049635

J. Hahn, M. Nordmann-kleiner, T. K. Hoffmann, and J. Greve, Thrombosis of the internal jugular vein in the ENT-department-Prevalence, causes and therapy: A retrospective analysis, Auris. Nasus. Larynx, 2018.

H. G. Watson, D. M. Keeling, M. Laffan, R. C. Tait, and M. Makris, Guideline on aspects of cancer-related venous thrombosis, Br. J. Haematol, vol.170, pp.640-648, 2015.

M. Di-nisio, A. Y. Lee, M. Carrier, H. A. Liebman, and A. A. Khorana, Subcommittee on Haemostasis and Malignancy. Diagnosis and treatment of incidental venous thromboembolism in cancer patients: guidance from the SSC of the ISTH, J. Thromb. Haemost. JTH, vol.13, pp.880-883, 2015.

G. H. Lyman, K. Bohlke, A. A. Khorana, N. M. Kuderer, A. Y. Lee et al., Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.33, pp.654-656, 2014.

A. G. Shuman, H. M. Hu, C. J. Pannucci, C. R. Jackson, C. R. Bradford et al., Stratifying the risk of venous thromboembolism in otolaryngology. Otolaryngol.-Head Neck Surg, Off. J. Am. Acad. Otolaryngol.-Head Neck Surg, vol.146, pp.719-724, 2012.

I. Watzke and H. Watzke, Thromboembolic risk factors in patients undergoing maxillofacial surgery for malignancies. Oral Surg. Oral Med. Oral Pathol, vol.67, pp.137-140, 1989.

S. P. Moubayed, A. Eskander, M. W. Mourad, and S. P. Most, Systematic review and meta-analysis of venous thromboembolism in otolaryngology-head and neck surgery, Head Neck, vol.39, pp.1249-1258, 2017.

S. Molnar, H. Guglielmone, M. Lavarda, M. L. Rizzi, and G. Jarchum, Procoagulant factors in patients with cancer, Hematol. Amst. Neth, vol.12, pp.555-559, 2007.

J. Brayton, Z. Qing, M. N. Hart, J. C. Vangilder, and Z. Fabry, Influence of adhesion molecule expression by human brain microvessel endothelium on cancer cell adhesion, J. Neuroimmunol, vol.89, pp.104-112, 1998.

A. Rousseau, P. Van-dreden, A. Khaterchi, A. K. Larsen, I. Elalamy et al., Procoagulant microparticles derived from cancer cells have determinant role in the hypercoagulable state associated with cancer, Int. J. Oncol, vol.51, pp.1793-1800, 2017.

A. Saghazadeh and N. Rezaei, Inflammation as a cause of venous thromboembolism, Crit. Rev. Oncol. Hematol, vol.99, pp.272-285, 2016.

F. Posch, J. Thaler, G. Zlabinger, O. Königsbrügge, S. Koder et al., Soluble Vascular Endothelial Growth Factor (sVEGF) and the Risk of Venous Thromboembolism in Patients with Cancer: Results from the Vienna Cancer and Thrombosis Study (CATS), Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.22, pp.200-206, 2016.

J. H. Mcvey, The role of the tissue factor pathway in haemostasis and beyond, Curr. Opin. Hematol, vol.23, pp.453-461, 2016.

A. E. Mast, Tissue Factor Pathway Inhibitor: Multiple Anticoagulant Activities for a Single Protein, Arterioscler. Thromb. Vasc. Biol, vol.36, pp.9-14, 2016.

E. Sierko, M. Z. Wojtukiewicz, L. Zimnoch, and W. Kisiel, Expression of tissue factor pathway inhibitor (TFPI) in human breast and colon cancer tissue, Thromb. Haemost, vol.103, pp.198-204, 2010.

M. Z. Wojtukiewicz, E. Sierko, L. R. Zacharski, L. Zimnoch, B. Kudryk et al., Tissue factor-dependent coagulation activation and impaired fibrinolysis in situ in gastric cancer, Semin. Thromb. Hemost, vol.29, pp.291-300, 2003.

A. A. Khorana and R. L. Fine, Pancreatic cancer and thromboembolic disease, Lancet Oncol, vol.5, pp.655-663, 2004.

M. Z. Wojtukiewicz, D. Hempel, J. Kruszewska, L. Zimnoch, W. Kisiel et al., Erythropoietin receptor and tissue factor are coexpressed in human breast cancer cells, J. BUON Off. J. Balk. Union Oncol, vol.20, pp.1426-1431, 2015.

N. Magnus, D. Garnier, and J. Rak, Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells, Blood, vol.116, pp.815-818, 2010.

M. Z. Wojtukiewicz, L. R. Zacharski, M. Ruciñska, L. Zimnoch, J. Jaromin et al., Expression of tissue factor and tissue factor pathway inhibitor in situ in laryngeal carcinoma, Thromb. Haemost, vol.82, pp.1659-1662, 1999.

A. Christensen, K. Kiss, G. Lelkaitis, K. Juhl, M. Persson et al., Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer, BMC Cancer, vol.17, p.572, 2017.

M. Chang, C. Chan, Y. Ho, J. Lee, P. Lin et al., Signaling pathways for induction of platelet aggregation by SAS tongue cancer cells-A mechanism of hematogenous metastasis, J. Oral Pathol. Med. Off. Publ. Int. Assoc. Oral Pathol. Am. Acad. Oral Pathol, vol.38, pp.434-440, 2009.

J. Welsh, J. D. Smith, K. R. Yates, J. Greenman, A. Maraveyas et al., Tissue factor expression determines tumour cell coagulation kinetics, Int. J. Lab. Hematol, vol.34, pp.396-402, 2012.

M. A. Adesanya, A. Maraveyas, and L. A. Madden, Cancer microvesicles induce tissue factor-related procoagulant activity in endothelial cells in vitro, Blood Coagul. Fibrinolysis Int. J. Lab. Hematol, vol.28, pp.365-372, 2017.

B. Wang, S. Xiong, Q. Hua, C. Chen, H. Liao et al., Tissue factor is strongly expressed in pericarcinomatous tissue in patients with laryngeal carcinoma, Int. J. Clin. Exp. Pathol, vol.8, pp.13719-13724, 2015.

M. A. Kurer, Protein and mRNA expression of tissue factor pathway inhibitor-1 (TFPI-1) in breast, pancreatic and colorectal cancer cells, Mol. Biol. Rep, vol.34, pp.221-224, 2007.

E. Vairaktaris, Z. Serefoglou, C. Yapijakis, A. Vylliotis, E. Nkenke et al., High gene expression of matrix metalloproteinase-7 is associated with early stages of oral cancer, Anticancer Res, vol.27, pp.2493-2498, 2007.

M. Z. Wojtukiewicz, E. Sierko, L. Zimnoch, L. Kozlowski, and W. Kisiel, Immunohistochemical localization of tissue factor pathway inhibitor-2 in human tumor tissue, Thromb. Haemost, vol.90, pp.140-146, 2003.

Y. Nobeyama, E. Okochi-takada, J. Furuta, Y. Miyagi, K. Kikuchi et al., Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas, Int. J. Cancer, vol.121, pp.301-307, 2007.

Y. Sun, M. Xie, M. Liu, D. Jin, and P. Li, Growth suppression of human laryngeal squamous cell carcinoma by adenovirus-mediated tissue factor pathway inhibitor gene 2, Laryngoscope, vol.116, pp.596-601, 2006.

J. Thaler, M. Preusser, C. Ay, A. Kaider, C. Marosi et al., Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients, Thromb. Res, vol.131, pp.162-165, 2013.

M. Z. Wojtukiewicz, M. Rucinska, L. Zimnoch, J. Jaromin, Z. Piotrowski et al., Expression of prothrombin fragment 1+2 in cancer tissue as an indicator of local activation of blood coagulation, Thromb. Res, vol.97, pp.335-342, 2000.

A. Kalan, M. Tariq, R. P. Harar, and D. Gatland, Spontaneous internal jugular vein thrombosis and recurrent laryngeal nerve palsy: A rare simultaneous presentation of an occult malignant neoplasm, J. Laryngol. Otol, vol.110, pp.1166-1168, 1996.

T. Wakasaki, H. Kiyohara, H. Omori, K. Nishi, K. Taguchi et al., Massive internal jugular vein tumor thrombus derived from squamous cell carcinoma of the head and neck: two case reports, Oral Maxillofac. Surg, vol.21, pp.69-74, 2017.

H. Matsuno, O. Kozawa, K. Okada, S. Ueshima, O. Matsuo et al., Plasmin generation plays different roles in the formation and removal of arterial and venous thrombus in mice, Thromb. Haemost, vol.87, pp.98-104, 2002.

T. Kosugi, I. Takagi, Y. Ariga, S. Okada, T. Morimitsu et al., Fibrinolysis-coagulation system in patients with cancer of the head and neck, Arch. Otorhinolaryngol, vol.236, pp.211-215, 1982.

B. Jagielska, M. Symonides, E. Stachurska, A. Kawecki, and E. Kraszewska, Coagulation disorders in patients with locally advanced head and neck cancer-Should they really be disregarded? Neoplasma, vol.58, pp.129-134, 2011.

B. Hundsdorfer, H. Zeilhofer, K. P. Bock, P. Dettmar, M. Schmitt et al., Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity-Clinical relevance and prognostic value, J. Cranio-Maxillo-fac. Surg. Off. Publ. Eur. Assoc. Cranio-Maxillo-fac. Surg, vol.33, pp.191-196, 2005.

M. S. Serpa, R. P. Mafra, S. I. Queiroz, L. P. Da-silva, L. B. De-souza et al., Expression of urokinase-type plasminogen activator and its receptor in squamous cell carcinoma of the oral tongue, Braz. Oral Res, vol.32, 2018.

E. A. Baker, D. J. Leaper, J. P. Hayter, and A. J. Dickenson, Plasminogen activator system in oral squamous cell carcinoma, Br. J. Oral Maxillofac. Surg, vol.45, pp.623-627, 2007.

Y. Hayashido, T. Hamana, Y. Yoshioka, H. Kitano, K. Koizumi et al., Plasminogen activator/plasmin system suppresses cell-cell adhesion of oral squamous cell carcinoma cells via proteolysis of E-cadherin, Int. J. Oncol, vol.27, pp.693-698, 2005.

S. Nozaki, Y. Endo, S. Kawashiri, K. Nakagawa, E. Yamamoto et al., Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis, Oral Oncol, vol.34, pp.58-62, 1998.

E. Vairaktaris, C. Yapijakis, E. Nkenke, S. Vassiliou, A. Vylliotis et al., The 1040C/T polymorphism influencing thermal stability and activity of thrombin activatable fibrinolysis inhibitor is associated with risk for oral cancer, Am. J. Hematol, vol.82, pp.1010-1012, 2007.

H. Sakai, T. Suzuki, Y. Takahashi, M. Ukai, K. Tauchi et al., Upregulation of thromboxane synthase in human colorectal carcinoma and the cancer cell proliferation by thromboxane A2, FEBS Lett, vol.580, pp.3368-3374, 2006.

A. Mitrugno, S. Tassi-yunga, J. L. Sylman, J. Zilberman-rudenko, T. Shirai et al., The role of coagulation and platelets in colon cancer-associated thrombosis, Am. J. Physiol.-Cell Physiol, vol.316, pp.264-273, 2018.

S. Pinto, L. Gori, O. Gallo, S. Boccuzzi, R. Paniccia et al., Increased thromboxane A2 production at primary tumor site in metastasizing squamous cell carcinoma of the larynx, Prostaglandins Leukot. Essent. Fatty Acids, vol.49, pp.527-530, 1993.

G. J. Slotman, Plasma thromboxane A2 and prostacyclin concentrations in squamous cell carcinoma of the head and neck, J. Surg. Oncol, vol.38, pp.33-37, 1988.

M. Camacho, Z. Piñeiro, S. Alcolea, J. García, J. Balart et al., Prostacyclin-synthase expression in head and neck carcinoma patients and its prognostic value in the response to radiotherapy, J. Pathol, vol.235, pp.125-135, 2015.

P. Mir-seyed-nazari, J. Riedl, I. Pabinger, and C. Ay, The role of podoplanin in cancer-associated thrombosis, Thromb. Res, vol.164, pp.34-39, 2018.

Y. Kubouchi, Y. Yurugi, M. Wakahara, T. Sakabe, T. Haruki et al., Podoplanin expression in cancer-associated fibroblasts predicts unfavourable prognosis in patients with pathological stage IA lung adenocarcinoma, Histopathology, vol.72, pp.490-499, 2018.

J. Suchanski, A. Tejchman, M. Zacharski, A. Piotrowska, J. Grzegrzolka et al., Podoplanin increases the migration of human fibroblasts and affects the endothelial cell network formation: A possible role for cancer-associated fibroblasts in breast cancer progression, PLoS ONE, vol.12, 2017.

P. Yuan, S. Temam, A. El-naggar, X. Zhou, D. D. Liu et al., Overexpression of podoplanin in oral cancer and its association with poor clinical outcome, Cancer, vol.107, pp.563-569, 2006.

E. Martín-villar, F. G. Scholl, C. Gamallo, M. M. Yurrita, M. Muñoz-guerra et al., Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas, Int. J. Cancer, vol.113, pp.899-910, 2005.

M. Kreppel, M. Scheer, U. Drebber, L. Ritter, and J. E. Zöller, Impact of podoplanin expression in oral squamous cell carcinoma: Clinical and histopathologic correlations, Virchows Arch. Int. J. Pathol, vol.456, pp.473-482, 2010.

M. Pépin, A. Kleinjan, D. Hajage, H. R. Büller, M. Di-nisio et al., Mahé, I. ADAMTS-13 and von Willebrand factor predict venous thromboembolism in patients with cancer, J. Thromb. Haemost. JTH, vol.14, pp.306-315, 2016.

M. Franchini, F. Frattini, S. Crestani, C. Bonfanti, and G. Lippi, Willebrand factor and cancer: A renewed interest, Thromb. Res, vol.131, pp.290-292, 2013.

J. D. Sweeney, K. M. Killion, C. F. Pruet, and M. B. Spaulding, Von Willebrand factor in head and neck cancer, Cancer, vol.66, pp.2387-2389, 1990.

R. Paczuski, A. Bialkowska, M. Kotschy, D. Burduk, and S. Betlejewski, Von Willebrand factor in plasma of patients with advanced stages of larynx cancer, Thromb. Res, vol.95, pp.197-200, 1999.

H. Loghmani and E. M. Conway, Exploring traditional and nontraditional roles for thrombomodulin, vol.132, pp.148-158, 2018.

T. Oikawa, M. Kushuhara, S. Ishikawa, J. Hitomi, A. Kono et al., Production of endothelin-1 and thrombomodulin by human pancreatic cancer cells, Br. J. Cancer, vol.69, pp.1059-1064, 1994.

M. Hamatake, T. Ishida, T. Mitsudomi, K. Akazawa, and K. Sugimachi, Prognostic value and clinicopathological correlation of thrombomodulin in squamous cell carcinoma of the human lung, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.2, pp.763-766, 1996.

M. Tabata, K. Sugihara, S. Yonezawa, S. Yamashita, and I. Maruyama, An immunohistochemical study of thrombomodulin in oral squamous cell carcinoma and its association with invasive and metastatic potential, J. Oral Pathol. Med. Off. Publ. Int. Assoc. Oral Pathol. Am. Acad. Oral Pathol, vol.26, pp.258-264, 1997.

R. Hernández-gaspar, J. R. De-los-toyos, C. Alvarez-marcos, J. R. Riera, and A. Sampedro, Quantitative immunohistochemical analyses of the expression of E-cadherin, thrombomodulin, CD44H and CD44v6 in primary tumours of pharynx/larynx squamous cell carcinoma and their lymph node metastases, Anal. Cell. Pathol. J. Eur. Soc. Anal. Cell. Pathol, vol.18, pp.183-190, 1999.

C. Cui, G. Wang, S. Yang, S. Huang, R. Qiao et al., Tissue Factor-bearing MPs and the risk of venous thrombosis in cancer patients: A meta-analysis, Sci. Rep, vol.8, 1675.

J. G. Ren, Q. W. Man, W. Zhang, C. Li, X. P. Xiong et al., Elevated Level of Circulating Platelet-derived Microparticles in Oral Cancer, J. Dent. Res, vol.95, pp.87-93, 2016.

E. Sierko, M. Sobierska, E. Zabrocka, M. My?liwiec, J. Kruszewska et al., Endothelial Microparticles and Blood Coagulation Activation in Head and Neck Cancer Patients Undergoing Radiotherapy or Radiochemotherapy, vol.33, pp.627-632, 2019.

A. Aharon and B. Brenner, Microparticles, thrombosis and cancer, Best Pract. Res. Clin. Haematol, vol.22, pp.61-69, 2009.

B. R. Branchford and S. L. Carpenter, The Role of Inflammation in Venous Thromboembolism, Front. Pediatr, vol.6, 2018.

G. Grignani and A. Maiolo, Cytokines and hemostasis, Haematologica, vol.85, pp.967-972, 2000.

O. Gallo, S. Pinto, S. Boccuzzi, M. Dilaghi, E. Gallina et al., Monocyte tumor necrosis factor production in head and neck squamous cell carcinoma, Laryngoscope, vol.102, pp.447-450, 1992.

R. R. Parks, S. D. Yan, and C. C. Huang, Tumor necrosis factor-alpha production in human head and neck squamous cell carcinoma, Laryngoscope, vol.104, pp.860-864, 1994.

Y. Nakano, W. Kobayashi, S. Sugai, H. Kimura, and S. Yagihashi, Expression of tumor necrosis factor-alpha and interleukin-6 in oral squamous cell carcinoma, Jpn. J. Cancer Res. Gann, vol.90, pp.858-866, 1999.

N. N. Scheff, Y. Ye, A. Bhattacharya, J. Macrae, D. N. Hickman et al., Tumor necrosis factor alpha secreted from oral squamous cell carcinoma contributes to cancer pain and associated inflammation, vol.158, pp.2396-2409, 2017.

O. Gallo, A. M. Gori, M. Attanasio, F. Martini, B. Giusti et al., Interleukin-1 beta and interleukin-6 release by peripheral blood monocytes in head and neck cancer, Br. J. Cancer, vol.68, pp.465-468, 1993.

C. C. Tsai, C. C. Chen, C. C. Lin, C. H. Chen, T. S. Lin et al., Interleukin-1 beta in oral submucous fibrosis, verrucous hyperplasia and squamous cell carcinoma tissues, Kaohsiung J. Med. Sci, vol.15, pp.513-519, 1999.

G. R. Thomas, Z. Chen, E. Leukinova, C. Van-waes, and J. Wen, Cytokines IL-1 alpha, IL-6, and GM-CSF constitutively secreted by oral squamous carcinoma induce down-regulation of CD80 costimulatory molecule expression: restoration by interferon gamma, Cancer Immunol. Immunother. CII, vol.53, pp.33-40, 2004.

Y. Wang, S. Chang, S. Tai, W. Li, and L. Wang, Clinical significance of interleukin-6 and interleukin-6 receptor expressions in oral squamous cell carcinoma, Head Neck, vol.24, pp.850-858, 2002.

A. A. Khorana, S. A. Ahrendt, C. K. Ryan, C. W. Francis, R. H. Hruban et al., Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.13, pp.2870-2875, 2007.

Z. Chen, P. S. Malhotra, G. R. Thomas, F. G. Ondrey, D. C. Duffey et al., Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.5, pp.1369-1379, 1999.

S. Johnstone and R. M. Logan, Expression of vascular endothelial growth factor (VEGF) in normal oral mucosa, oral dysplasia and oral squamous cell carcinoma, Int. J. Oral Maxillofac. Surg, vol.36, pp.263-266, 2007.

R. J. Eisma, J. D. Spiro, and D. L. Kreutzer, Vascular endothelial growth factor expression in head and neck squamous cell carcinoma, Am. J. Surg, vol.174, pp.513-517, 1997.

A. Falanga, M. Marchetti, V. Evangelista, S. Manarini, E. Oldani et al., Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor, Blood, vol.93, pp.2506-2514, 1999.

E. A. Mann, J. D. Spiro, L. L. Chen, and D. L. Kreutzer, Cytokine expression by head and neck squamous cell carcinomas, Am. J. Surg, vol.164, pp.567-573, 1992.

L. Plantureux, L. Crescence, F. Dignat-george, L. Panicot-dubois, and C. Dubois, Effects of platelets on cancer progression, Thromb. Res, vol.164, pp.40-47, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02060300

J. Folkman, Proceedings: Tumor angiogenesis factor, Cancer Res, vol.34, pp.2109-2113, 1974.

S. Shigetomi, Y. Imanishi, K. Shibata, N. Sakai, K. Sakamoto et al., VEGF-C/Flt-4 axis in tumor cells contributes to the progression of oral squamous cell carcinoma via upregulating VEGF-C itself and contactin-1 in an autocrine manner, Am. J. Cancer Res, vol.8, pp.2046-2063, 2018.

A. Subarnbhesaj, M. Miyauchi, C. Chanbora, A. Mikuriya, P. T. Nguyen et al., Roles of VEGF-Flt-1 signaling in malignant behaviors of oral squamous cell carcinoma, PLoS ONE, vol.12, 2017.

R. Chen, G. Jin, W. Li, and T. M. Mcintyre, Epidermal Growth Factor (EGF) Autocrine Activation of Human Platelets Promotes EGF Receptor-Dependent Oral Squamous Cell Carcinoma Invasion, Migration, and Epithelial Mesenchymal Transition, J. Immunol. Baltim. Md, vol.201, pp.2154-2164, 1950.

W. Dai, Y. Li, Q. Zhou, Z. Xu, C. Sun et al., Cetuximab inhibits oral squamous cell carcinoma invasion and metastasis via degradation of epidermal growth factor receptor, J. Oral Pathol. Med. Off. Publ. Int. Assoc. Oral Pathol. Am. Acad. Oral Pathol, vol.43, pp.250-257, 2014.

H. Zhang, J. Sun, L. Yan, and X. Zhao, PDGF-D/PDGFR? promotes tongue squamous carcinoma cell (TSCC) progression via activating p38/AKT/ERK/EMT signal pathway, Biochem. Biophys. Res. Commun, vol.478, pp.845-851, 2016.

C. Chen, M. Zimmermann, I. Tinhofer, A. M. Kaufmann, and A. E. Albers, Epithelial-to-mesenchymal transition and cancer stem(-like) cells in head and neck squamous cell carcinoma, Cancer Lett, vol.338, pp.47-56, 2013.

F. Wu, K. J. Weigel, H. Zhou, and X. Wang, Paradoxical roles of TGF-? signaling in suppressing and promoting squamous cell carcinoma, Acta Biochim. Biophys. Sin, vol.50, pp.98-105, 2018.

J. S. Palumbo, K. E. Talmage, J. V. Massari, C. M. La-jeunesse, M. J. Flick et al., Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells, Blood, vol.105, pp.178-185, 2005.

K. Egan, N. Cooke, and D. Kenny, Living in shear: Platelets protect cancer cells from shear induced damage, Clin. Exp. Metastasis, vol.31, pp.697-704, 2014.

S. Mezouar, R. Darbousset, F. Dignat-george, L. Panicot-dubois, and C. Dubois, Inhibition of platelet activation prevents the P-selectin and integrin-dependent accumulation of cancer cell microparticles and reduces tumor growth and metastasis in vivo, Int. J. Cancer, vol.136, pp.462-475, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01773064

M. L. Papa, F. Capasso, L. Pudore, S. Torre, S. Mango et al., Thromboelastographic profiles as a tool for thrombotic risk in digestive tract cancer, Exp. Oncol, vol.29, pp.111-115, 2007.

M. P. Crowley, M. P. Crowely, S. Quinn, E. Coleman, J. A. Eustace et al., Differing coagulation profiles of patients with monoclonal gammopathy of undetermined significance and multiple myeloma, J. Thromb. Thrombolysis, vol.39, pp.245-249, 2015.

A. Zanetto, M. Senzolo, A. Vitale, U. Cillo, C. Radu et al., Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma, Dig. Liver Dis. Off. J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liver, vol.49, pp.440-445, 2017.

, This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, © 2019 by the authors. Licensee MDPI